<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00053989</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000269673</org_study_id>
    <secondary_id>RP01-05</secondary_id>
    <nct_id>NCT00053989</nct_id>
  </id_info>
  <brief_title>NMA Allogeneic Hematopoietic Cell Transplant in Hematologic Cancer/Disorders</brief_title>
  <official_title>Non-Myeloablative Allogeneic Hematopoietic Peripheral Blood Stem Cell Transplantation for Hematologic Malignancies and Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roswell Park Cancer Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Roswell Park Cancer Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Giving low doses of chemotherapy before a donor peripheral blood stem cell
      transplant helps stop the growth of cancer cells. It also stops the patient's immune system
      from rejecting the donor's stem cells. The donated stem cells may replace the patient's
      immune system and help destroy any remaining cancer cells (graft-versus-tumor effect). Giving
      an infusion of the donor's T cells (donor lymphocyte infusion) after the transplant may help
      increase this effect. Sometimes the transplanted cells from a donor can also make an immune
      response against the body's normal cells. Giving immunosuppressive therapy before or after
      the transplant may stop this from happening.

      PURPOSE: This phase II trial is studying how well chemotherapy followed by donor peripheral
      stem cell transplant works in treating patients with hematologic cancer or aplastic anemia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

        -  Determine the safety and toxic effects of nonmyeloablative allogeneic peripheral blood
           stem cell transplantation in patients with a hematologic malignancy or aplastic anemia.

        -  Determine clinical response and overall outcome of patients treated with this regimen.

        -  Determine the incidence of graft-vs-tumor effect, graft-vs-host disease, and chimerism
           in patients treated with this regimen.

      OUTLINE:

        -  Preparative regimen:

             -  Matched related and unrelated donor transplantation:

                  -  Patients receive cyclophosphamide IV over 2 hours on days -5 and -4 and
                     fludarabine IV over 30 minutes on days -5 to -1.

             -  Cord blood transplantation:

                  -  Patients receive the same regimen as above plus anti-thymocyte globulin IV
                     over 4 hours on days -3 to -1.

        -  Graft-vs-host disease (GVHD) prophylaxis:

             -  Matched related and unrelated donor transplantation:

                  -  Patients receive oral tacrolimus (or IV) once daily and oral mycophenolate
                     mofetil (MMF) (or IV) twice daily on days -1 to 60 followed by tapering* of
                     this regimen. Patients then receive methotrexate IV on days 1, 3, and 6.

             -  Cord blood transplantation:

                  -  Patients receive tacrolimus and MMF in the same regimen as above plus
                     methylprednisolone twice daily on days 1-19 or until blood counts recover.

        -  Allogeneic stem cell reinfusion: Patients undergo allogeneic bone marrow or peripheral
           blood stem cell transplantation on day 0. Patients then receive sargramostim (GM-CSF)
           subcutaneously daily beginning on day 7 and continuing until blood counts recover.

        -  Donor lymphocyte infusion (DLI): Patients not converting to 100% donor T-cell chimerism
           by day 120 and showing signs of progresson of disease after tacrolimus and MMF
           withdrawal may receive DLI every 8 weeks for up to 3 infusions. Cord blood recipients do
           not receive DLI.

      Patients are followed at day 100-120, every 3 months for 2 years, and then every 6 months for
      5 years.

      PROJECTED ACCRUAL: A total of 30-60 patients will be accrued for this study within 6-7 years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 29, 2002</start_date>
  <completion_date type="Actual">July 19, 2018</completion_date>
  <primary_completion_date type="Actual">July 19, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Day 100 TRM</measure>
    <time_frame>from start or conditioning (day -6 or -5) through day +100 after HSC infusion</time_frame>
    <description>treatment related mortality within 100 days from hematopoietic stem cell (HSC) infusion on day 0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Day 100 Best Response</measure>
    <time_frame>from start of conditioning on day -6 or -5 through day +100 after HSC infusion</time_frame>
    <description>Best disease response measured within 100 days from hematopoietic stem cell (HSC) infusion on day 0 using disease specific response criteria defined in the protocol</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>1 year</time_frame>
    <description>Progression free survival defined as time from HSC infusion (day 0) until progression of disease or death due to any cause. Patients are censored if alive without disease progression through 1 year after HSC infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>1 year</time_frame>
    <description>Overall survival with events defined as death due to any cause and censored patients are alive as of 1 year post HSC infusion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acute GvHD</measure>
    <time_frame>Day +100</time_frame>
    <description>overall grade II-IV acute GvHD</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Chronic Myeloproliferative Disorders</condition>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Myelodysplastic/Myeloproliferative Diseases</condition>
  <condition>Fanconi Anemia</condition>
  <condition>Aplastic Anemia</condition>
  <arm_group>
    <arm_group_label>All patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients enrolled on study</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
    <description>iv</description>
    <arm_group_label>All patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>graft-versus-tumor induction therapy</intervention_name>
    <description>iv</description>
    <arm_group_label>All patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>sargramostim</intervention_name>
    <description>iv</description>
    <arm_group_label>All patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic allogeneic lymphocytes</intervention_name>
    <description>iv</description>
    <arm_group_label>All patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>injection</description>
    <arm_group_label>All patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <description>iv</description>
    <arm_group_label>All patients</arm_group_label>
    <other_name>FLUDARA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methylprednisolone</intervention_name>
    <description>oral</description>
    <arm_group_label>All patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate mofetil</intervention_name>
    <description>oral</description>
    <arm_group_label>All patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus</intervention_name>
    <description>oral</description>
    <arm_group_label>All patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>allogeneic bone marrow transplantation</intervention_name>
    <description>iv</description>
    <arm_group_label>All patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <description>iv</description>
    <arm_group_label>All patients</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>umbilical cord blood transplantation</intervention_name>
    <description>iv</description>
    <arm_group_label>All patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Diagnosis of aplastic anemia

               -  Severe disease

               -  Failed at least 1 course of standard immunosuppressive regimen with cyclosporine
                  and anti-thymocyte globulin OR

          -  Histologically confirmed hematologic malignancy including the following:

               -  Acute leukemia

                    -  Any of the following types:

                         -  Acute myeloid leukemia (AML) with antecedent myelodysplastic syndromes

                         -  Secondary AML

                         -  AML with high-risk cytogenetic abnormalities

                         -  Acute lymphoblastic leukemia with high-risk cytogenetic abnormalities

                    -  Resistant or recurrent disease after combination chemotherapy with at least
                       1 standard regimen OR

                    -  In first remission at high risk of relapse

               -  Chronic myelogenous leukemia

                    -  Chronic phase meeting at least 1 of the following criteria:

                         -  Failed imatinib mesylate

                         -  Failed interferon after at least 6 months of treatment with minimum of
                            21 million units of interferon per week

                         -  Unable to tolerate interferon

                    -  Accelerated phase (blasts less than 20%)

               -  Myeloproliferative and myelodysplastic syndromes

                    -  Myelofibrosis (after splenectomy)

                    -  Refractory anemia

                    -  Refractory anemia with excess blasts

                    -  Chronic myelomonocytic leukemia

               -  Lymphoproliferative disease

                    -  Chronic lymphocytic leukemia

                         -  Symptomatic disease after first-line chemotherapy

                    -  Low-grade non-Hodgkin's lymphoma (recurrent or persistent)

                         -  Symptomatic disease after first-line chemotherapy

                    -  Multiple myeloma

                         -  Progressive disease after autologous stem cell transplantation

                    -  Waldenstrom's macroglobulinemia

                         -  Failed 1 standard regimen

               -  Non-Hodgkin's lymphoma meeting the following criteria:

                    -  Intermediate or high grade

                    -  Controlled and chemosensitive disease

                    -  First remission lymphoblastic or small non-cleaved cell lymphoma at high
                       risk of relapse

               -  Hodgkin's lymphoma

                    -  Relapsed and chemosensitive disease

          -  Not eligible for standard myeloablative allogeneic stem cell transplantation

          -  Availability of any of the following donor types:

               -  Related donor matched at 5 or 6 HLA antigens (A, B, DR)

               -  Unrelated donor fully matched by molecular analysis at A, B, DRB1, and DQB1 loci

                    -  Single antigen mismatch at C allowed

               -  Cord blood that is 4, 5, or 6 match with recipient HLA antigens (A, B, DR) NOTE:
                  No syngeneic donors permitted

          -  No uncontrolled CNS disease (for hematologic malignancies) NOTE: A new classification
             scheme for adult non-Hodgkin's lymphoma has been adopted by PDQ. The terminology of
             &quot;indolent&quot; or &quot;aggressive&quot; lymphoma will replace the former terminology of &quot;low&quot;,
             &quot;intermediate&quot;, or &quot;high&quot; grade lymphoma. However, this protocol uses the former
             terminology.

        PATIENT CHARACTERISTICS:

        Age

          -  4 to 75 (if related or unrelated donor peripheral blood or marrow transplantation)

          -  4 to 60 (if unrelated cord blood transplantation)

        Performance status

          -  Karnofsky &gt; 50%

        Life expectancy

          -  Not specified

        Hematopoietic

          -  Not specified

        Hepatic

          -  Bilirubin less than 3 times normal

          -  Alkaline phosphatase less than 3 times normal

          -  AST/ALT less than 3 times normal

          -  No Child's class B or C liver failure

        Renal

          -  Creatinine clearance greater than 40 mL/min

        Cardiovascular

          -  Cardiac ventricular ejection fraction at least 35% by MUGA

          -  No cardiovascular disease

        Pulmonary

          -  DLCO at least 40% of predicted, corrected for hemoglobin and/or alveolar ventilation

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  HIV antibody negative

          -  No uncontrolled diabetes mellitus

          -  No active serious infection

          -  No other disease that would preclude study therapy

          -  No other concurrent malignancy except non-melanoma skin cancer

          -  No concurrent serious psychiatric illness

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  See Disease Characteristics

          -  patients may have received a prior autologous blood or marrow transplantation (BMT)

          -  At least 6 months since prior allogeneic BMT

        Chemotherapy

          -  See Disease Characteristics

          -  At least 2 weeks since prior chemotherapy, radiation or surgery

        Endocrine therapy

          -  Not specified

        Radiotherapy

          -  At least 2 weeks since prior radiotherapy

        Surgery

          -  At least 2 weeks since prior surgery
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Philip L. McCarthy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roswell Park Cancer Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Roswell Park Cancer Institute</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>February 5, 2003</study_first_submitted>
  <study_first_submitted_qc>February 5, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 6, 2003</study_first_posted>
  <results_first_submitted>December 19, 2019</results_first_submitted>
  <results_first_submitted_qc>January 29, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 10, 2020</results_first_posted>
  <last_update_submitted>January 29, 2020</last_update_submitted>
  <last_update_submitted_qc>January 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>accelerated phase chronic myelogenous leukemia</keyword>
  <keyword>chronic myelomonocytic leukemia</keyword>
  <keyword>primary myelofibrosis</keyword>
  <keyword>de novo myelodysplastic syndromes</keyword>
  <keyword>chronic phase chronic myelogenous leukemia</keyword>
  <keyword>relapsing chronic myelogenous leukemia</keyword>
  <keyword>refractory anemia with excess blasts</keyword>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>Waldenstrom macroglobulinemia</keyword>
  <keyword>stage III adult lymphoblastic lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
  <keyword>stage III adult Burkitt lymphoma</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>adult acute myeloid leukemia in remission</keyword>
  <keyword>secondary acute myeloid leukemia</keyword>
  <keyword>recurrent childhood acute lymphoblastic leukemia</keyword>
  <keyword>recurrent adult acute myeloid leukemia</keyword>
  <keyword>childhood acute lymphoblastic leukemia in remission</keyword>
  <keyword>adult acute lymphoblastic leukemia in remission</keyword>
  <keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>refractory anemia</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>previously treated myelodysplastic syndromes</keyword>
  <keyword>secondary myelodysplastic syndromes</keyword>
  <keyword>grade 1 follicular lymphoma</keyword>
  <keyword>grade 2 follicular lymphoma</keyword>
  <keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
  <keyword>recurrent adult acute lymphoblastic leukemia</keyword>
  <keyword>recurrent childhood acute myeloid leukemia</keyword>
  <keyword>childhood acute myeloid leukemia in remission</keyword>
  <keyword>childhood chronic myelogenous leukemia</keyword>
  <keyword>atypical chronic myeloid leukemia</keyword>
  <keyword>myelodysplastic/myeloproliferative disease, unclassifiable</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>adult acute myeloid leukemia with t(8;21)(q22;q22)</keyword>
  <keyword>adult acute myeloid leukemia with t(16;16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with inv(16)(p13;q22)</keyword>
  <keyword>adult acute myeloid leukemia with 11q23 (MLL) abnormalities</keyword>
  <keyword>adult acute myeloid leukemia with t(15;17)(q22;q12)</keyword>
  <keyword>childhood myelodysplastic syndromes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Anemia, Aplastic</mesh_term>
    <mesh_term>Myeloproliferative Disorders</mesh_term>
    <mesh_term>Fanconi Anemia</mesh_term>
    <mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Sargramostim</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 19, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/89/NCT00053989/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>All Patients</title>
          <description>All patients enrolled on study Patients received cyclophosphamide 50 mg/kg on days -5 and -4, and fludarabine 25 mg/m2 on days -5, -4, -3, -2, -1.
Hematopoietic cells from peripheral blood or marrow were infused on day 0. Patients who received hematopoietic cells from cord blood additionally received ATG 30 mg/kg on days -3, -2, -1.
Fanconi anemia patients received cyclophosphamide 7.5 mg/kg on days -6, -5, -4, -3, fludarabine 25 mg/m2 on days -6, -5, -4, -3, -2 and ATG 30 mg/kg on days -3, -2, -1 and hematopoietic cells infused on day 0.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="41"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>All Patients</title>
          <description>All patients enrolled on study Patients received cyclophosphamide 50 mg/kg on days -5 and -4, and fludarabine 25 mg/m2 on days -5, -4, -3, -2, -1.
Hematopoietic cells from peripheral blood or marrow were infused on day 0. Patients who received hematopoietic cells from cord blood additionally received ATG 30 mg/kg on days -3, -2, -1.
Fanconi anemia patients received cyclophosphamide 7.5 mg/kg on days -6, -5, -4, -3, fludarabine 25 mg/m2 on days -6, -5, -4, -3, -2 and ATG 30 mg/kg on days -3, -2, -1 and hematopoietic cells infused on day 0.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="41"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52" lower_limit="5" upper_limit="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diagnosis</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Acute lymphoblastic or myeloid leukemia</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Hodgkin/non-Hodgkin lymphoma/prolymphocytic leukem</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Multiple Myeloma</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Myelodysplastic syndrome</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Fanconi anemia</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Day 100 TRM</title>
        <description>treatment related mortality within 100 days from hematopoietic stem cell (HSC) infusion on day 0</description>
        <time_frame>from start or conditioning (day -6 or -5) through day +100 after HSC infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Patients</title>
            <description>All patients enrolled on study</description>
          </group>
        </group_list>
        <measure>
          <title>Day 100 TRM</title>
          <description>treatment related mortality within 100 days from hematopoietic stem cell (HSC) infusion on day 0</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Day 100 Best Response</title>
        <description>Best disease response measured within 100 days from hematopoietic stem cell (HSC) infusion on day 0 using disease specific response criteria defined in the protocol</description>
        <time_frame>from start of conditioning on day -6 or -5 through day +100 after HSC infusion</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Patients</title>
            <description>All patients enrolled on study</description>
          </group>
        </group_list>
        <measure>
          <title>Day 100 Best Response</title>
          <description>Best disease response measured within 100 days from hematopoietic stem cell (HSC) infusion on day 0 using disease specific response criteria defined in the protocol</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Complete Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Partial Response</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Early Death/NE</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Response/Stable Disease</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Progressed</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PFS</title>
        <description>Progression free survival defined as time from HSC infusion (day 0) until progression of disease or death due to any cause. Patients are censored if alive without disease progression through 1 year after HSC infusion</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Patients</title>
            <description>All patients enrolled on study</description>
          </group>
        </group_list>
        <measure>
          <title>PFS</title>
          <description>Progression free survival defined as time from HSC infusion (day 0) until progression of disease or death due to any cause. Patients are censored if alive without disease progression through 1 year after HSC infusion</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27" lower_limit="13" upper_limit="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OS</title>
        <description>Overall survival with events defined as death due to any cause and censored patients are alive as of 1 year post HSC infusion</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>All Patients</title>
            <description>All patients enrolled on study</description>
          </group>
        </group_list>
        <measure>
          <title>OS</title>
          <description>Overall survival with events defined as death due to any cause and censored patients are alive as of 1 year post HSC infusion</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="41"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44" lower_limit="29" upper_limit="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Acute GvHD</title>
        <description>overall grade II-IV acute GvHD</description>
        <time_frame>Day +100</time_frame>
        <population>2 participants died before they were eligible for this outcome</population>
        <group_list>
          <group group_id="O1">
            <title>All Patients</title>
            <description>All patients enrolled on study</description>
          </group>
        </group_list>
        <measure>
          <title>Acute GvHD</title>
          <description>overall grade II-IV acute GvHD</description>
          <population>2 participants died before they were eligible for this outcome</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>100 days</time_frame>
      <desc>SAE=died before absolute neutrophil count recovery (DBE) or survived to day +28 without absolute neutrophil count recovery (FTE) AE=overall grade III-IV acute GVHD</desc>
      <group_list>
        <group group_id="E1">
          <title>All Patients</title>
          <description>All patients enrolled on study</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>Serious</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="41"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>DBE/FTE</sub_title>
                <description>died before absolute neutrophil count recovery (DBE) or survived to day +28 without absolute neutrophil count recovery (FTE)</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>Other</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>acute GVHD grade III-IV</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="41"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Theresa Hahn, PhD</name_or_title>
      <organization>Roswell Park Comprehensive Cancer Center</organization>
      <phone>716084505819</phone>
      <email>theresa.hahn@roswellpark.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

